DSI Business Development
Daiichi Sankyo Business Development
At Daiichi Sankyo, we have a firm commitment to flexibility and transparency for all our alliances in service to making any collaboration greater than the sum of its parts. By creating tailored business models for each asset, we have built a history of strong, successful partnerships in the interest of rapidly bringing innovative therapies to patients. Our oncology pipeline is one of the strongest in the industry with great potential for transforming the way diseases are treated.
Our early research team focuses on new approaches to care, leveraging our world-class technology and expertise. Together with our partners, we believe we can transform standards of care.
Our therapeutic areas of interest include:
Earlier stage approaches & platforms, including:
- Discovery platform for tumor environment-dependent functional peptides
- Antibodies (including VHH antibodies), peptides, or small molecules with high penetration and retention in tumor stroma
- New targets for gene therapy
Oncology, later stage assets:
- Post-preclinical or clinical-stage oncology programs with the potential to combine with DXd-based ADCs (or topoisomerase I inhibitors) to improve clinical outcomes by broadening the addressable population or increasing the duration of response.
- Mechanisms of action of interest potentially include some of the following:
- Cell Cycle regulation
- TKI (Tyrosine Kinase Inhibitors) in priority indications
- DDR (DNA Damage Response)n
Non-oncology, late-stage assets (phase 2 ongoing or later) regional partnerships
Non-oncology, research, including psychiatric disorders, cardiovascular, and others
For additional areas of interest in early research, visit our Open Innovation site: https://www.daiichisankyo.com/rd/strategy_operations/open_innovation/
Partner with us
Please contact us to start a conversation about how we can work together to improve patient lives. We have business development colleagues located globally, in Tokyo, Japan, the United States and in Europe. Please submit your confidential licensing or alliance proposal for consideration here: Submit non-confidential proposal